Vmn1r30 inhibitors are a class of chemical compounds that specifically target the Vmn1r30 receptor, a member of the vomeronasal 1 receptor family, which is part of the broader group of G-protein-coupled receptors (GPCRs). The Vmn1r receptors are primarily involved in chemosensory detection, playing a role in the processing of chemical signals such as pheromones in certain species. The Vmn1r30 receptor is located in the vomeronasal organ (VNO), a specialized structure in some vertebrates responsible for detecting chemical cues. Inhibitors of Vmn1r30 function by binding to the receptor or altering its interaction with natural ligands, thereby preventing the receptor from transmitting its normal signaling cascades in response to chemical stimuli.
The development and study of Vmn1r30 inhibitors involve exploring the receptor's molecular structure and its binding interactions with various ligands. Structural biology techniques such as molecular modeling, ligand docking studies, and biochemical assays are used to characterize how these inhibitors block receptor function. These inhibitors can be valuable for probing the specific roles of Vmn1r30 in the broader context of chemosensory pathways, helping to clarify how the receptor contributes to cellular signaling and behavioral responses to chemical stimuli. By inhibiting this receptor, researchers can gain a deeper understanding of the molecular mechanisms governing chemosensory detection, receptor activation, and the subsequent biological processes without referencing any external applications. This precise targeting of Vmn1r30 provides essential insights into the role of individual receptors within the complex network of GPCR-mediated signaling systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist, can modulate GPCR signaling, potentially affecting Vmn1r30 indirectly. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, may alter GPCR-mediated processes, potentially impacting Vmn1r30. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Serotonin receptor antagonist, might affect GPCR signaling pathways, influencing Vmn1r30 indirectly. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect noradrenergic signaling, possibly related to Vmn1r30. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase, increasing cAMP levels, which could modulate GPCR signaling affecting Vmn1r30. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Angiotensin II receptor antagonist, might modulate GPCR pathways, potentially influencing Vmn1r30 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker, could affect calcium signaling pathways, potentially related to Vmn1r30. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Inhibits Gi/o proteins, could affect GPCR-mediated signaling pathways involved with Vmn1r30. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r30. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r30 function. | ||||||